EVH — Evolent Health, Inc. stock price, charts and financials

QT38Evolent Health, Inc.

Evolent Health, Inc. (NYSE: EVH) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.14
+0.05+1.62%
EVHQT38Evolent Health, Inc.·NYSE
3.14+1.62%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-4.68Insider Own5.59%Shs Outstand112.48MPerf Week-26.78%
Market Cap347.57MForward P/E9.00EPS next Y0.34Insider Trans0.00%Shs Float107.68MPerf Month-46.17%
Enterprise Value1.17BPEG0.00EPS next Q-Inst Own-Short Float13.64%Perf Quarter-17.60%
Income-499.07MP/S0.18EPS this Y103.86%Inst Trans-Short Ratio5.70Perf Half Y-4.63%
Sales1.89BP/B0.87EPS next Y89.96%ROA-26.43%Short Interest14.69MPerf YTD-22.75%
Book/sh-P/C10.39EPS next 5Y42.26%ROE-77.89%52W High10.47 -70.00%Perf Year-68.79%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-1.08%52W Low2.13 47.14%Perf 3Y-89.63%
Dividend Est.-EV/EBITDA-Sales past 3/5Y11.54% 15.19%Gross Margin14.13%Volatility10.93% 8.09%Perf 5Y-85.85%
Dividend TTM-EV/Sales0.62EPS Y/Y TTM-477.78%Oper. Margin-0.86%ATR (14)0.41Perf 10Y-86.57%
Dividend Ex-Date-Quick Ratio1.32Sales Y/Y TTM-26.07%Profit Margin-26.29%RSI (14)23.96Recom2.27
Dividend Gr. 3/5Y-Current Ratio1.32EPS Q/Q-133.33%SMA20-38.88%Beta0.74Target Price6.88
Payout-1.32%Debt/Eq2.49Sales Q/Q2.48%SMA50-35.07%Rel Volume1.55Prev Close3.09
Employees4,200LT Debt/Eq2.35EarningsAug 06SMA200-25.29%Avg Volume2.92MPrice3.14
IPO DateJun 05, 2015Option/ShortYes / YesEPS/Sales Surpr.58.81% -7.07%Net Debt/EBITDA-2.61Volume4,524,013Change1.62%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-23-26DowngradeCitigroupBuyNeutral
Jul-21-26ReiteratedCanaccord GenuityBuy$6.00$7.00
Jun-30-26DowngradeTruist SecuritiesBuyHold$6.00$7.00
May-12-26ReiteratedCanaccord GenuityBuy$6.00
Feb-25-26ReiteratedBMO Capital$3.50
Feb-25-26DowngradeKeybancOverweightSector Weight
Feb-02-26ReiteratedBTIGBuy$10
Dec-02-25ReiteratedPiper SandlerOverweight$6.00
Jan-16-25ReiteratedUBSBuy
Jan-14-25ReiteratedRBC CapitalOutperform
Latest News
Jul-28-26
Jul-23-26
Jul-20-26
Jul-17-26
Jul-16-26
Jul-08-26
Jul-03-26
Jul-01-26
Jun-29-26
Jun-12-26
Company

Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,8891,8762,5551,9641,352908925687627
Cost of Goods Sold Incl. D&A1,6221,5922,1871,5031,035658697513328
Gross Profit267284367460317250228174299
Selling, General and Administrative Excl. Other283288263358269219210236306
Research and Development00002700018
Other Operating Expense00145174177428124727
Operating Income-16-4-40-714-42-263-309-47
Interest Expense64572554162528155
Unusual Expense
Non-Operating Income (Expense)-417-4732-77-5038-39-7-1
Net Income Before Taxes-498-535-63-202-62-30-331-330-54
Income Taxes-10-1-89-430-2-230
Consolidated Net Income-497-535-62-113-19-38-334-302-53
Net Income From Continuing Operations-497-535-62-113-19-30-328-307-54
Net Income-497-535-62-113-19-38-334-302-53
EPS (Recurring)-4.68-5.07-0.81-1.28-0.20-0.36-3.94-3.71-0.68
EPS (Basic, Before Extraordinaries)-4.68-5.07-0.81-1.28-0.20-0.36-3.94-3.71-0.68
EPS (Diluted)-4.68-5.07-0.81-1.28-0.20-0.36-3.94-3.71-0.68
EBITDA-315-36185-254456-241-255-4
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio0.190.240.511.871.952.621.471.082.45
Gross Margin14.1315.1414.3623.4223.4527.5324.6525.3347.69
Operating Margin-0.85-0.21-1.57-3.620.30-4.63-28.43-44.98-7.50
Net Margin-26.31-28.52-2.43-5.75-1.41-4.19-36.11-43.96-8.45
Shares Outstanding1121141151119486858277
Market Capitalization3524561,2943,6662,6402,3801,3637421,536
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$13.23$10.11$6.98$3.85$0.73 Close Price0.00K9.55K19.10K28.65K38.20KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Springstubb Brendan BDirectorNov 18 '25Buy3.8210,00038,19958,821Nov 19
Jelinek Richard MDirectorMar 07 '25Buy9.1330,000273,75015,000Mar 10
Springstubb Brendan BDirectorMar 07 '25Buy9.2715,000139,05026,842Mar 10
KECK KIMDirectorMar 07 '25Buy9.4410,54099,49839,522Mar 10
McCarthy Daniel JosephPRESIDENTMar 06 '25Buy9.0111,04099,470389,004Mar 10
Blackley SethChief Executive OfficerMar 06 '25Buy9.0155,225497,577762,217Mar 10
Holder DianeDirectorMar 06 '25Buy9.332,73525,51870,584Mar 10
GRUA PETER JDirectorMar 06 '25Buy9.0111,04099,47018,749Mar 10
Barbarosh Craig A.DirectorMar 06 '25Buy8.812,00017,62031,956Mar 10
Glass Russell MonroeDirectorMar 06 '25Buy9.275,40050,05814,272Mar 10
Springstubb Brendan BDirectorMar 04 '25Buy8.755,00043,75011,842Mar 05
McCarthy Daniel JosephPRESIDENTAug 23 '24Sale32.3810,469339,008188,340Aug 26
Blackley SethChief Executive OfficerAug 22 '24Sale30.00187,9045,637,120411,924Aug 26
McCarthy Daniel JosephPRESIDENTAug 22 '24Option Exercise24.754,550112,613222,502Aug 26
McCarthy Daniel JosephPRESIDENTAug 22 '24Sale30.8923,693731,790198,809Aug 26
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.